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Introduction
More than 25 years after the identif ication of HIV as rhe
causative agent of AIDS, the disease continues to spread
in some countries [1]. Current antiretrovirals (ARVs) have
significantly prolonged the time to both AIDS develop-
ment and death in those infecced with HIV [2], although
ARV success has ultimately been limited by toxicity,
drug-drug interactions and other factors that determine
patient compliance and, consequently, the emergence of
resistance. Thus, there is a continuous need for existing
agents to be improved and for the development of new
drugs and drug classes that are effective, safe, have a
higher genetic barrier to resistance. penetrare viral reser-
voirs more effectively and have activity against resisrant
viruses. Another challenge is to develop strategies that
maximize the efficacy of currently available drugs for as
long as possible; how to start, when to start, how to change
and when to change ARV therapy (ART) are all crucial
elements of this strategy. However, it should be noted
that access to new drugs and strategies erves no purpose
if the chain of new infections is not broken and if the low
levels of prevention and education that are currently in
place persist. Unfortunately, relative to the advances
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Purpose of review
To discuss new antiretroviral agents (ARVs) and alternative ARV treatment strategies
that are currently being evaluated, and to provide an overview oÍ the most recent
advances in HIV vaccine development.
Recent findings
There is a continuous need for improvements in ARV therapy (ART) and several new
ARVs are currently undergoing cl inical investigatìon, including the non-nucleoside
reverse transcriptase inhibitor r i lpivir ine, the integrase inhibitor elvi tegravir,  the
chemokine receptor 5 co-receptor antagonist vicr iviroc and the maturation inhibitor
bevir imat. Strategies to optimize ART, such as treatment interruption, induction-
maintenance and class-sparing regimens, are also being evaluated and have had
varying success to date. However, vaccination st i l l  remains the optimal solut ion, and one
second-generation preventative HIV vaccine has produced encouraging results in a
recent phase l l l  tr ia!.
Summary
Global prevention and treatment with ARVs that are effect ive, well  tolerated and have
high barriers to the development of HIV resistance are the main strategies to f ight HIV/
AIDS while we await the develooment of an effect ive vaccine.
Keywords
antiretrovirals, HlV, strategies, vaccination
Cur  Op ln  HIV AIDS 6 (supp l  1 ) :S2 i  -S30
O 2011 Wolters Kluwer Health I  Lipp ncott Wil l iams & Wilkins1 746-630X
made in treatment, prevention strategies have lagged
behind considerably. The creation of an HIV vaccine
represents the greatest hope for globally controll ing the
pandemic and preventing further socio-economic
damage, and this wil l be the most important concern
of the scientif ic communitv during this century. Owing to
numerous factors, including the current lack of an effec-
tive HIV vaccine. there has been recent enthusiasm
regarding the potential use of effective ART to prevent
transmission of HIV, although well-designed trials are
needed to determine the efficacy and feasibil i ty of this
st rategy t3 l .  ln  th is  rer  ier , r .  \Àe summarize recent
advances in ARV agents, in ARV therapeutic straregies
and in HIV vaccine develooment.
Overview of new ARVs under investigation
Several new ARVs are currently undergoing clinical
evaluation, most of which are new members of existing
drug classes, such as non-nucleoside reverse transcriptase
inhibitors (NNRTIs), integrase inhibitors or chemokine
receptor 5 (CCRS) inhibitors [4]. The aim of such 'next-
generation' agents is to improve upon the l imitations of
currently used drugs, including sensitivity, resiscance and
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tolerabil ity. Moreover, as many of these agents are being
evaluated for once-daily administration, the1, may poten-
tially confer some beneÍìts in terms of compliance. How-
ever, there are few new agents under investigation that
are derived from natural products, leaving this an area
deserving of further research effort [4].
Rilpivirine
Rilpivirine (TN,IC278), a diarylpyrimidine derivative, is a
second-generation NNRTI, which is active against wild-
tvpe HIV-1 and strains that are already resistant to other
\ \RT ls .  R i l p i v i r i ne  i s  a  po ten t  reve rse  t ransc r i p tese
inhibitor and its antiviral activitv is additive to that of
other ARVs.
Rilpivirine demonstrated antiviral efficacy in patients
naìve to therapy in phase II cl inical studies [5',6] and,
as a result, is currently being evaluated in treatment-
naïr'e patients in two ongoing 96-week, randomized,
double-b l ind,  phase I I I  t r ia ls ,  known as ECHO and
THRIVE. Prelirninary pooled 4S-u'eek data from the
phase III tr ials (n : 1368) suggest that once-daily ri lpi-
virine 25 mg provides virological suppression noninferior
to that of efavirenz, when used in combination with
nucleoside reverse transcriptase inhibitors (NRTIs),
with most patients in both treatment groups achieving
HIV-I RNA levels of <50copies/ml (84.3% vs 82.3Vo;
between-group difference 2.0% [95Vo Cl -2.0,6.01) l7'1.
\loreover, ri lpivirine appears to have a good tolerabil itv
profi le. The most common adverse reactions to occur
rvith ri lpivirine in various trials included nausea, vonrit-
ing, headache and dizziness. Although ri lpivirine was
associated u.ith a l0% incidence of rash and, a 30Vo
incidence of neuropslrchiatric disorders, the incidence
<lf these events was lower than with the comoarator.
Rilpivirine offers the convenience of once-daily oral
dosing (2.5 mg), and long-acting parenteral formulations
are also uncler investigation [8]. Oral ri lpivirine should
alwavs be taken with food, as it increases exposure to the
drug by 45% l9l.However, drugs, such as rifampicin, that
induce the cl,tochrome P450 (CYP) enzvme, CYP3A,l,
can reduce ri lpivirine exposure and should therefore not
be co-adminis tered wi th r i lp iv i r ine [10] .  Use of  drugs
that increase gastrointestinal pH, such as proton pump
inhib i tors (e.g.  omeprazole)  and H2-receptor  antagonists
(e.g. famotidine), may also reduce ri lpivirine exposure
[11,12] .  Consequent ly ,  proton purn;r  inh ib i tors should
not  be coadminis tered wi th r i lp iv i r ine [11] ;  H2-receptor
antagonists can be used, provided thev are administered
several hours before or after ri lpivirine [12].
'fhree 
mutations have been identif ied as being associated
rvith decreased susceptibil i ty to ri lpivirine in 'uìÍro
(K101P, Y1u1I  and Y181V) and the res is tance prof i le
of ri lpivirine appears to be more robust than those of
first-generation NNRTIs [13]. T'hus, ri lpivirine mav
represent a viable future NNR'Ì'I treatment option for
ART-naïve patients and, l ike the second-generation
NNRTI etravirine, mav potentially have use in the
treatment of HlV-infected patients with resiscance to
other NNRTIs, althor-rgh its use in this setting has vet
to be evaluated.
Elvitegravir
Elv i tegravi r  (GS-9137) is  an HIV integrase inhib i tor  that
inhibits the integration of viral DNA into the host's
chromosomal )NA. 'fhe drug has demonstrated potent
antiviral activity against viruses r,r ' i th resiscance to
NNRTIs, NRTIs and protease inhibitors (PIs).
The antiviral efficacy of elvitegravir has been assessed
preclominantly in treatment-experienced ;latients. One
randomized, dose-ranging, phase II studv (n : 278)
compared the efficacy of once-clail-v elvitegravir 20, .50
or I 2.5 mg boosted with ritonavir u'ith that of a comparator
ritonavir-boosted PI (PI/r), in combination rvith an active
backgrouncl regimen, in treatment-experienced patients
[14']. The elvitegravir arms \\ 'ere found to be nonin-
ferior (50mg/day) or statistically superior (12.5 mg/dav;
p-0.021) to the PI / r  arm u ' i th  regard to the t in- ìe-
weighted average change from baseline in HIV RNA
levels through week 2,1 of therapy (-1.4,+ and -1.66 r's
-1.19 logtocopies/ml- ;  in tent- to- t reat  [ ' fT]  analys is) .
However, the elvitegravir 20mgJda.v treatment arm \\ 'as
prematurely terminated following a review rif the data at
8 weeks lr 'hich found high rates of virological failure. Use
of a PI/r (clarunavir/r or t ipranavir/r) r 'vas permitted after
week 8 in the remaining elvitegravir arms. As a result, the
16-week timepoint u'as considered to be che latest t ime-
point least l ikely to be affected by anv potentiall-y con-
fbunding effects of PI/r addition; however, the findings at
16 weeks corroboratecl those of the 2'l-u'eek analvsis.
In addition, two ongoing, randomized, double-blincl,
phase III tr ials are currentlv comparing once-dail-v elvi-
tegravir/r with twice-daily raltegravir, in combination
with a background regimen (a PI/r plus a second agent),
in  t reatment-exper ienced pat ients [15,16] .
Elvitegravir is metabolized by CYP3A4 and pharmaco-
logical studies have sholvn that it can be boosted rvith
100mg of  r i tonavi r  adminis tered once dai ly .  In  combi-
nation u,ith ritonavir, the oral bioavailabil itv of elvitegra-
v i r  is  increased and i ts  systemic exposure is  increased
=Z0-fold. As an alternative to ritonavir, the non-ritonayir
boosting agent cobicistat is being evaluatecl. Elvitegravir
has been coformulated u'ith emtricitabine, tenofovir dis-
oproxil fumarate (DF') and cobicistat in a single t:rblet for
once-dai ly  adrn in is t rat ion. ' fh is  f ixed-dose combinat ion
(the Quad pil l) was recently compared with once-
daily f ixed-dose efavirenz/tenofovir DF/emtricitabine
v
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(AtriplaiL' ') in a randomized, double-blind, phase II tr ial in
treatment-naïve patients (n - 71) [17']. N'lost patients in
each treatment group achieved an HIV RNA level of
<50copies/ml after 2,1 weeks of therapy (90% vs 83%;
lT"I' analysis), with the Quad pil l  meeting criteria for
noninferiority relative to AtriplaiBr.
Elvitegravir/r does not appear to require dosage adjust-
ment when co-administered r,vith NR'l ' Is or NNRTIs
[10,18]. Similarly, the elvicegravir dosage (150mg/day)
does not require adjustment upon co-administration with
darunavir/r, t ipranavir/r or fosamprenavir/r [10,18,19],
although should be reduced to 85 mg/day in combination
r.vith atazanavir/r or lopinavir/r 120,211. The pharmacoki-
netics of elvitegravir/r are unaitered when coadminis-
tered 'uvith the CCR.5 inhibitor maraviroc, although as
exposure to maraviroc is increased, a reduced maraviroc
dosage may be requircd l?21.
With regard to other drugs, the dosage of rifabutin should
be reduced to 150m9 once daily or three times weekly
r,vhen coadministered with elvitegrav:r' lr 1231. Dosage
adjustments are not required when elvitegravir/r is taken
rvith omeprazole, although elvitegravir/r and antacids
should be administered at least Zhours apart owing to
a reduction in elvitegravir exposrrre upon coadministra-
t ion [24] .
Elvitegravir demonstrated a good tolerabil ity profi le in
the phase II tr iai, with the most commonly reported
adverse events being upper respiratory tract infection,
diarrhoea, nausea ancl fatigue [14']. The integrase
n'ìutations that developed most commonlv with elvite-
gravir in this trial included 8148R/H/K, Nl55H, E92Q
and E13BK [25]. Notably, raltegravir has been shown to
select for mutations at these incegrase amino acid pos-
itions in aioo and evidence for cross-resistance between
elvitegravir and raltegravir has been observed [25].
Owing to its activity against HIV strains with resistance to
other ARVs ancl its efficacy in treatment-experienced
patients to date, elvitegravir should be a welcome
addition to current salvage therapy options, particularly
as it can be administered once daily. However, given the
potentiallv low chreshold for resistance associated with
integrase inhibitors, monotherapy should be avoided
t261.
Vicriviroc
\, ' icriviroc maleate (SCH 417690; hereafter referred to as
vicriviroc) is a new CCR.5 co-receptor antagonist, a class
of drugs thac bind specificallv to the CCR5 co-receptor of
the host cell, preventing entry of the virus. 'I 'he antiviral
activit)r of vicriviroc is generally similar to that of mar-
aviroc (the first approved drug in this class), which is
indicated for use in treatment-experienced pacienrs.
Vicriviroc, as a component of combination ART, was
shown to provide virological suppression for up to
48 weeks in treatment-experienced patients infected
with CCR5-tropic HIV in randomized, double-blind,
phase I I  t r ia ls ,  known as VICTOR-E1 (n:114)  and
ACTG 5211 (n -  118)  127 -291,  wi th an open- label  exten-
sion of VICTOR-E1 indicacing sustained antivirai
efficacy with vicriviroc for up to 96 weeks [30]. Con-
sequently, the efficacy of the drug in CCR5-tropic HIV-
infected treatment-experience d patients is currently
being evaluated in two identically designed, randomized,
double-b l ind,  phase I I I  t r ia ls  (n:857 randomized),
known as VIC-I'OR-E3 and VICTOR-E,+, in which
patients are treated with vicriviroc 30 mg or placebo once
daily, in combination with an optimized background
regimen (OBR) consisting of at least two ARVs. Pooled
data from these studies showed no difference betll'een
che vicriviroc and placebo groups for the proportion of
patients with an HIV RNA level of <50 copies/ml after
,18 u' 'eeks of therapy (61Vo vs 6l%) I3l '1. However,
vicriviroc appeared to be effective in those who had
two or fewer ARVs in their OBR (70% vs 55% of placebo
recip ients;  p -  0.02)  in  fur ther  analyses [31 ' ] .
In addicion, the efficacy of vicriviroc 30 mg once daily
is currently being compared with that of tenofovir
DF/emtricitabine, each in combination with atazanavirfr,
in treatment-naïve patients with CCR5-tropic HIV infec-
tion in a phase III study [32]. Ifeffective, such a nucleoside-
sparing first-l ine creatment regimen would enable other
classes of agents to be withheld for subsequent i ines
of therapy. Of note, an earlier phase II tr ial in treatment-
naïve patients was terminated prematurely owing to ln
increased rate of virological failure in those who received
vicriviroc 25 or 50 mg once daily relative to those who
received efavirenz, each in combination with a dual NRTI
regimen [33].
Adverse events, such as headache (15%) and diarrhoea
(10%) have been reported with vicriviroc. However, there
is no record of serious side effects in humans, in particular
those involving the central nervous system (CNS), such
as seizures, which have occurred in animal species at
very high plasma concentrations of vicriviroc. Further-
more, vicriviroc does not appear to be associated with
serious laboratory or electrocardiographic abnormalit ies.
Although certain malignancies developed in some treat-
ment-experienced patients who participated in the phase
II ACTG trial involving vicriviroc, a causal relationship
with che drug was not considered to be determinable [28]
and no new malignancies occurred during the excended
follow-up of the trial [29].
Vicriviroc is metabolized primarily by CYP3A4, has a
half-l i fe of 28-33hours (enabling once-dailv adminis-
tration) and can be adminiscered with or without food
Y
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[10,34]. N{<lreover, no dosage adjustment seems ro be
necessary when ritonavir is used in combination with
v icr iv i roc [10] .  However,  as v icr iv i roc is  a CCRS co-
receptor antagonist, it is vital that a viral tropism tesr is
performed before init iating treatment; if rhe viral strain
uses the chernokine (CXC motif l recepror 4 (CXCR4) co-
receptor or both CXCR4 and CCR.5 (i.e. is dual-tropic),
v icr iv i roc should not  be used [3.5,36] .
Bevirimat
Bevirimat (PA-4-57) belongs to a novel class of ARVs
known as maturation inhibitors and has been studied
in phase I and II tr ials [37-39]. The drug works by
specificallv inhibit ing the final stage in Gag processing,
namelv the conversion of the capsid precursor (CA-SP1/
p2.5) to the capsid protein (C^lp?a). After treatment with
bevirimat, the viral particles released by the infected cells
have abnormal structures and are therefbre non-infec-
tious.
Bevirimat has demonstrated antiviral activitv even in
patients infected with resistant viruses. Its administracion
in con-rbination with other ARVs appears to be safe, and
in ttitt'o it clemonstrates svnergv with approved ARVs.
Bevirimat has good oral bioavailabil ity an<1 a long half-l i fe
of about 2 clays, enabling once-<Jaily administration;
however, it is sti l l  unknown which dosage wil l prove to
be the mrist effective. The drug is metabolized by
glucuronidation and seems to have no clrug interacrions.
In ttìtro, for reasons 1,et unknown, strains of HIV already
resistant to PIs show hypersuscepribil irv to bevirimat
[40j. Further clevelopment of bevirimat has currently
been susocnded.
count. Although exploratory studies seemed promising,
the more recently completed trials that used a CD4- cell
count guided approach, including TRIVACAN (n - 386)
[44], STACCATO (n:430) [45] and the large SNIART
studv (n:5472) [,161, showed a higher inciclence of mor-
biditv, not only opportunistic diseases and death, but also
renal, hepatic and cardiovascular events, in the treatment
interruption arms than in the continuous therapy arms.
These data do not support the general use <lf treatment
interruption as a simplif ication strategy in HlV-infected
individuals [43], except perhaps in selected populations.
Single-drug-class therapy \\.as init ially studied with
NRTIs, including both once-daily and fixe<ì-dose triple
combinations [47-.50]. However, these trials generallv
showed a greater risk of virological failure u'ith NRTIs
than with NNRTI-based regimens when used in the
init ial rreatment of HIV infection.
Like NRTIs, PIs (which combine potency with a high
genetic barrier to resistance) have also been studiecl as
monotherapy. Lopinavir/r has been the PI most exten-
sively studied in this setting, with data available from six
randomized controlled studies. One such studv is the
N{ONARK tr ia l  (n:138) ,  which compared lopinavi r / r
with the triple combination of lopinavir/r, zidovudine
and lamivudine in AR'f-naïve patients wich CD4- cell
counts of > 100 cells/p,l- and HIV RNA levels of
<100,000copies/mL [.51]. There were no significant
differences between the treatment groups in terms of
virological suppression after 24 or 48 weeks of therapv in
the ITT analysis. However, major PI mutations were
detected in 3 of 21 patients with virological failure in the
lopinavir/r alone arm and in none of those with virological
failure in the triple-therapy arm.
In a recent systematic revieu, of all Pl-monotherapy
studies published in peer-reviewed journals or presented
at conferences up to 2008 1521, the overall efficacv ofPI/r
monotherapy was found to be inferior to that of HAAR'I,
although the efficacy was improved if patienrs were
started on monotherapy after having virological suppres-
sion for at least 6 months. 'I 'his strategy is called induc-
tion-maintenance and is based on the assumption that
after a phase of maximal suppressive HAAR'f (induc-
tion), the same level of viral suppression could be
maintained by fewer drugs (maintenance). -frials using
NRTIs and/or a Íìrst-generation PI as mainrenance
therapv have produced variable findings [53-58], but
PI/r monotherapy maintenance has also been studied
in the past few years. Advantages of this approach would
be reduction of side effects (including avoidance of
long-term NRTI toxicity) ancl fewer drug inreracrions
and costs. One further benefit could be reduction of ARV
resistance, as failure of PI/r regimens seldom selects for
major PI resistance mutations.
Overview oÍ new ARV therapeutic strategies
Although eraclication of HIV remains an elusive prospect,
ART is now able to maintain viral suppression in infectecl
individuals, preserving their imrnune sysrems for pro-
longed perio<ìs of t ime. The current standard of care fbr
the treatment of HIV in the developecl world is highly
active ART (HAART), usually a combination of two
NRTIs ancl an NNRTI or Pl l4l,1Zl. However, concerns
sti l l  exisr regarcling the long-term toxicity associated with
chronic drug exposure, the need for daily medication
adherencc, the developmenc of HIV resistance, drug-
drug interactions and the costs associated with treatment.
Several drug-sparing strategies are being explored to
minimize ARV requirements. ' Ì 'hese inc lude intermir renr
therap_v, induction-maintenance regimens rnd class-spar-
ing combinat ions [ ,13] .
Intermittent therapy was first thought ro be a srraregy rhar
could reduce drug exposure and toxicitv, and usuallv
consists of predefined periods on and off therapv, or
scheduled treatnìent interruptions guided bv CD4+ cell
'Y
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Atazanavir/r, a once dailv Pl/r vl ' i th a good metabolic
profi le, u.as studiecl as maintenance monotherapy in
sm:rl l, non-comparative trials [.59-61]. Virologic suppres-
sion u'as generallv nìaintained, although one study was
prematurely stopped because of an excess of virologic
failures [591. Reassuringly, no major PI mutations could
be detected in the virologic failures, either by standard
ge notvping or bv single genome sequencing that detects
low frequency mutations. This finding reaÍïrms the
results of ;rrevious trials showing that PI resistance
mutations are uncomrnon when PI monotherapy fails.
'I 'he 
more Íecently appÍoved Pl, darunavir/r, has also
been studied as maintenance monotherap_v. Tu'o large
tr ia ls  (NIONE' l '1621and NIONOI-ANRS 136 [63])  com-
paring darunavir/r monotherapy with darr-rnavir/r plus a
double nucleoside backbone in virologicallv suppressed
patients were presentecl at the 2009 International AIDS
Society Conference. At 48 weeks in both trials, the
efficacv of the monotherapy arm was noninferior to that
of the standard triple regimen. Nloreover, in the three
patients who experienced viral failure in the NIONOI-
ANRS 136 trial no new mutations related to darunavir
resistance u'ere detectecl [63].
However, PI monotherapy simplif ication strategies remain
associated rvith concerns regarding l imited penetration of
the clrug into viral resevoirs ancl the possibil i ty of viral
replication in the CNS or genital tract [6,+]. With the
introduction of new classes of agents, such as integrase
inhibitors ancl CCR5 co-receptor antagonists, clther main-
tenance combinations arc possible, and studies are already
unclerway to explore these very well tolerated drugs as
components of alternative regimens [65]. In addition,
cornbining raltegravir, the first approved integrase inhibi-
tor, with a PI (either lopinavir/r, atazanavir or darunavir/r) is
cLlrrentl-v being explored as a potential class-sparing
approach in treatment-naiïe patients in several ongoing
studies [66-6tj]. Indeed, AR'l 'wil l  continue to be devel-
opecl, with the aim of re<lucing toxicity, improvrng con-
venicnce and enhancing the potency and durabil ity of
response, while preserving patient quality of l i fe.
Update on HIV vaccination reseaÍch
As currently available treatments are not effective in
cradicating HlV, vaccination represents the optimal
solution to the global impact of this infection. The
primary goal of an H IV vaccine is to prevent the establish-
rnent of a ;rersistent infection, with the ideal vaccine
being ablc to block infection completelv and provide
steril izing immunity [69]. However, an alternative, per-
haps more realistic, vaccination goal is to lower the
steadv-state viral load achieved after primary HIV-1
infection (i.e. the viral set point). A safe and effective
therapeutic vaccine that could reduce viral load could
potential ly reduce transmission, improve public health
outcomes and reduce costs associated with long-term
ART exposure. Nloreover, a vaccine capable of reducing
the need for ART may help to reduce the burden of
disease [70]. However, there are numerous obstacles to
generating effect ive vaccines against HIV-1, including
the remarkable diversity of the virus and i ts capacity to
evade selective pressures through genetic variat ion and to
establ ish latent viral reservoirs. and the fact that there is
no method to el ici t  broadly reactive antibody responses,
no clear immune correlates of orotection ancl no small-
animal models [691.
Humoral and cell-mediated immunity in HIV
infection
Vaccines induce memory immune responses that expand
upon pathogien exposure to prevent or control an infec-
tion. Nlemorv can be induced for both B and T'cells. B
cells produce antibodies, whereas CDS- T cells (cvto-
toxic T lvmphocytes ICTLs]) recognize and destrol, cells
that are virus infected. CD4+ T cells are often referred to
as "helper T cells" as they produce factors that are
required for thc growth and differentiation of CD8- T'
ce l ls  and B cel ls  [71] .
The general aim of a vaccine is to stimulate the pro-
duction of neutralizing antibodies. Hclwever, unlike other
infections, infection with HIV typically fails to provide
protective immunity that lasts. Within weeks of being
infected with HIV, circulating antibodies appear which
are the basis for the diagnostic HIV ELISA test, yet the
virus continues to destroy immune system cells, primarily
CD4-  ' l ' ce l l s  [ 72 ] .
How extensively HIV pathogenesis is controlled by
humoral and innate immunity is sti l l  unclear, although
one HIV antigen potentiallv relevant to prorective
humoral immunity is the envelope (Env) glycoprotein,
which exists as a trimer on the surface of the virus particle
[69,70]. N{any of the conserved epitopes of the Env gly-
coprotein of HIV-1 are shielded from antibody recognition
by extensive N-linked glycosylation 169,731, and some
conserved regions (e.g. the chemokine co-receptor binding
site) frlrm only after Env has bound to CD4- and under-
gone a subsequent change in conformationí69,741. More-
over, any N-linked glycan mutations that develop may also
facil i tate the evasion of neutralizing antibody responses
169,731. In spite of the progress that has been made in
understanding the structure and function of Env, no
candidate vaccines to elicit Enr'-specific, broadlv neutra-
l izing antibodies are currently being studied in clinical
trials.
Virus-specific 'I '- lymphocyte responses appear to play a
pivotal role in the control of HIV-1 replication and are
v
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consequently being investigated in vaccinarion srrar-
egies. Data indicate that during an acure HIV infection,
virus-specific CD8+ T-lymphocyte responses are coinci-
dent with primary viremia control [75,76]. However,
despite vigorous CD8- CTL responses directed ar che
virus, the majority of individuals fail to clear the infection,
perhaps because the selective pressure exerted by the
CTLs may drive viral mutational escape. This strongly
suggests that vaccines against persistent viruses should
elicit early and strong humoral responses in addition to
celÌular responses.
togenes, are also being investigated [69,78-80]. The con-
struction of recombinant viral vectors usually involves
the removal of important viral genes (thus rendering the
vector replication defective, potentially allowing for
€lreater safety) and then fi l l ing the resulting empty space
with genes for the desired vaccine antigens [78,81].
Plasmid DNA vaccines proved to be disappointing in
preclinical studies conducted in non-human primaces
[79], although in untreated HlV-infected patients the
first HIV DNA vaccines were safe and induced varying
immune responses [82]. T'he immunogenicity of the
vaccines could be improved by approaches such as pro-
moter modification or use of cytokine adjuvants or syn-
rhetic genes [79,821. However, DNA vaccines appear to
be most useful when used as the priming component of
prime-boost vaccination strategies that use l ive recombi-
nant vaccines for boostins.1791.
Several candidate HIV protein subunit vaccines have
been developed, the first of which employed the HIV-
1 envelope subunit proteins gp120 and gp160 (purif ied or
recombinant) with the hope of elicit ing neucralizing
antibodies against HIV-1 to tÍeat infection [70]. Lipopep-
tides represent another type of rherapeutic HIV vaccine,
the first of which was composed of a l ipid group cova-
lently coupled to a synthetic Gag peptide containing
several CTL epitopes restricted by varying HLA alleles.
Lipopeptide vaccines are capable of inducing CD4- and
CD8- T-cell responses to a variety of known and novel
T-cell epitopes [82]. Lipopeptides have shown promise
in trials, both alone and as adjuvants to facil i tate the
delivery of protein subunit vaccines and to boost other
therapeutic or prophylactic vaccines [70].
Antigen-presenting cells, such as dendrit ic cells (DC), are
ins t rumen ta l  i n  i nduc ing  an  immune  response  aga ins t
HIV, although their functional capacity declines during
the infection [70]. DCs have been investigated as a
potential therapeutic vaccine approach, with around
50% of patients who received DCs loaded with inacti-
vated autologous HIV-1 achieving viral load suppression
withour ART in one study [82]. However, in another trial,
administration of HIV peptide-loaded DCs followed by
HAAR'| interruption did not reduce viral set poinrs
beyond those observed before the init iation of HAART
1821.
Glinical tr ials using Í irst-generation HIV-1
vaccines
There are currently more than 30 trials evaluating pre-
ventive HIV vaccine candidates. However, despite a
number of promising phase I and II studies, the most
advanced candidates have so far been unsuccessful. In
init ial studies, HIV vaccine candidates with the hope of
Approaches for the development of an HIV
vaccine
Several types of vaccine are currently l icensed for human
use: l ive-attenuated viruses. whole inactivated viruses
and viral protein subunits 169,711. Although these
traditional technologies have been very successful in
generating vaccines against various viruses, they have
not yet yielded a successful HIV vaccine. In spite of the
fact that good short-term protection against the develop-
ment of infection has been seen wich l ive-attenuated
virus vaccines in non-human primates, the risks associ-
ated with using such HIV vaccines in humans have been
too high, owing to the potential for vaccines ro generare
virulent variants or cause disease in those who are immu-
nocompromised. Although animal models init ially gave
some hope for whole inactivated virus vaccines, the
protective immunity was later found to be mediated
bv antibodies against human cellular proteins presenr
in the outer membrane of the immunizing virus that
had been incorporated during its production in human
cell l ines. Both whole inactivated virus and viral protein
subunit vaccines provide immune protection mainly via
the elicitation ofantibodies, but such vaccines have so far
been unsuccessful in elicit ing protective antibodies
against HIV 17 l l. However, data from nonhuman
primates suggest that incorporating'I 'oll- l ike receptor
adjuvants into HIV protein subunit vaccination strategies
may increase their uti l i ty [77]. In addition to using
adjuvanced proteins and peptides in vaccination, other
new vaccine concepts and strategies include gene-deliv-
erv technologies (e.g. l ive recombinant viral vectors, or
DNA vaccines) and the combined use of at least rwo
antigen delivery modalit ies in heterologous prime/boost
regimens [69,71].
The use of viral vectors to deliver HIV antigens to
specific target cells is the main strategy currently being
explored. A great variety of viruses, including adeno-
viruses, poxviruses, parvoviruses, alphaviruses, paramyx-
oviruses, rhabdoviruses and herpesviruses, have been
used co construct l ive and infectious recombinant vectors
(e.g. ALVAC), and bacterial vaccine vectors, such as
Bacillus Calmette-Guérin, Salmonella <tr Lìsterìa mono.y-
--:+!JlllJl, \___/ o
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elicit ing humoral antibody responses were evaluated,
including synthetic peptides and recombinant proteins
[83]. In spite of being safe and well tolerated, the subunit
vaccine based on monomeric recombinant gp120 failed to
pÍotect against HIV-1 infeccion because the elicited anti-
bodies could not neutralize primary HIV- 1 isolaces, despite
showing some nelltralizing activity againsc laboratorv
strains ìn aìtro. Although early vaccine studies were unsuc-
cessful, manv lessons were learned from them as well as
from fundamental tesearch on the HIV trnv orotein.
Glinical trials using second-generation HIV-1
vaccines
Once the potential role of cell-mediated immune
responses in controll ing HIV infection was recognized,
researchers broadened cheir scope to evaluare vaccines
that incorporated the more conseÍved internal proteins of
HIV as well as the envelope, and gave more attention to
evaluating vaccines that induced both humoral and cell-
mediated responses.
A randomized, double-biind, placebo-controlled, phase-
III tr ial, known as RV144, was designed to evaluate the
efficacy of the ALVAC-HIV vaccine (a non-replicating
rcc<, ,mbinant  crnarvpox v i r r rs  vector  conta in ing genes
from HIV) boosted with the protein vaccine AIDSVAX
B/E (gp120) in preventing HIV-1 infection.'Ihe trial was
conducted in Thailand in 16,402 HlV-negative individ-
uals and the results were recently published [84"]. In the
modified ITT analvsis, the vaccine had an efficacy of
31.2% (p-0.04 vs placebo). Further analysis of the
immune responses generated in vaccinees is needed,
r'vith an attempt to identify a correlate of protection.
Follow-up clinical trials would also be beneficial in orcler
to fully understand the vaccine effect and the potential
for further vaccine development.
ln addition, phase I clinical trials have evaluated a tri-
valent mixture of recombinant adenovirus serotype 5
vectors (rAd5) expressing the Gag, Pol and Nef of clade
B HIV-I. f)ata from these studies suggeste<1 that, in
general, the vaccine was well tolerated and immuno-
genic, although pre-existing neutralizing antibodies
against the vaccine vector were seen ro partially suppress
the response to the vaccine [69]. Subsequently, two
"proof-of-concept" phase IIb efficacy studies, known
as Step [80] and Phambili [85], were init iated to deter-
mine if this vaccine could prevent HIV-1 infection or
reduce viral krads post-infection in adults at high risk of
HIV-1 infection. However, the studies were discontinued
in 2007 because of a failure of the STEP trial to meet its
efficacy enclpoints [80]. Furthermore, the vaccrne u,as
associated with a greater number of HIV-1 infections than
placebo in volunteers who had pre-existing Ad5-specific
neucraÌizing antibodv titers, seemingly suggesting that
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rAd5 vector vaccines may be associaced lvi th a higher,
rather than lower, r isk of contracting HIV in these indi-
viduals. Further analvsis of the acquisit ion data showed
a stat ist ical ly signif icant increased r isk of infeccion in
vaccinated men who were uncircumcised [80].
Future vaccine approaches
Further research intcl the structure. function and immu-
nogenicity of the Env glycoprotein is needed to faci l i tate
efforts in generating improved Env immunogens that are
capable of el ici t ing broad neutral izing antibodv responses
against HIV. However, as the optimal vaccine is l ikely
co be a combination vaccine capable of el ici t ing both
T-lymphocyte and neì,Ì tral izing-antibody Íesponses,
these two vaccine strategies should ideal ly be pursued
and developed simultaneously [69]. Some current
vaccine approaches, such as heterologous recombinant
adenovirus prime-boost regimens [69] or vaccine cocktai l
strategies [86], may offer new hope.
Conclusion
The prognosis of patients infected with HIV has
improved dramatically over the last 26 years owing ro
the introduction of numerous effective anti-HIV drugs.
However, l imitations, such as toxicity ancl the develop-
ment of resistance, have continuously clriven the search
for alternative agents, and several 'next-generation'
agents are currently in development. Given the consider-
able progress that has been made in the treatment of HIV
to dace, there is hope that future research wil l yield
effective novel therapies to further extencl the current
drug arsenal. In contrast, generating an effectir-c pÍeven-
tative or therapeutic vaccine against HIV has proven to be
much more diff icult. HIV vaccines that incorporate HI\, '
proteins/epitopes representing a broad range of strains
and that induce a strong cross-reacrive immune Íesponse
are needed, and aithough this has not yet been achieved,
the field of HIV vaccine research is progressing. How-
ever, as HIV vaccine development u'i l l  continue to be a
challenge, efficacy trials wil l certainlv require the collab-
oration of product developers, governments, funclers and
resea rchc rs  i n mu l t i p l e  coun t r i es .
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